The Wee1 inhibitor MK1775 (AZD1775) is currently being tested in clinical trials for cancer treatment. Here, we show that the p53 target and CDK inhibitor p21 protects against MK1775-induced DNA damage during S-phase. Cancer and normal cells deficient for p21 (HCT116 p21 -/-, RPE p21
Introduction
Cyclin dependent kinases (CDKs) in complex with different cyclins propel the progression of the cell cycle, and the activity of CDKs is therefore subject to strict regulation. Wee1 kinase phosphorylates CDK1 on tyrosine 15, and thereby restrains CDK activity in G2 phase [1, 2] . Accordingly, inhibition of Wee1 causes G2 checkpoint abrogation [3, 4] . Based on this, the Wee1 inhibitor MK1775 (AZD1775) is in clinical trials for cancer treatment in combination with radiotherapy or chemotherapeutic drugs [4] . Particularly, G2 checkpoint abrogation by MK1775 may be toxic for p53 mutated cancer cells lacking the p53-dependent G1 checkpoint [3] . However, Wee1 also plays a role in restraining CDK activity in S phase, through tyrosine 15 phosphorylation of both CDK1 and CDK2 [5] [6] [7] . Loss of Wee1 during S phase leads to aberrant CDK activity followed by unscheduled replication initiation and subsequent DNA damage [7, 8] . Such S phase damage has been termed replication catastrophe [9] and is likely a major cause behind single-agent antitumor activity of Wee1 inhibitors [10] . The mechanism of how Wee1 inhibition causes this DNA damage in S phase is not completely understood. Furthermore, more knowledge is needed about which factors contribute to resistance or sensitivity towards Wee1 inhibitors.
The p53 target and CDK inhibitor p21 plays a fundamental part in regulating cell cycle progression, as well as cellular senescence and apoptosis [11] . Although p21 mutations are uncommon, emerging evidence has shown that p21 expression can be low in cancer due to epigenetical suppression [12] [13] [14] [15] [16] . p21 inhibits CDK activity by binding cyclin-CDK complexes, and thereby induces the G1 checkpoint after DNA damage [17] [18] [19] . In addition, p21 has also been implicated in G2 checkpoint maintenance [20] . Furthermore, p21 has a strong affinity for PCNA, and prevents replication by blocking the interaction between PCNA and factors that are necessary for replication, such as replicative DNA polymerases [21, 22] . For this reason, p21 levels are reduced in S-phase in order for replication to occur. However, the remaining p21 may have important S-phase functions, as it is involved in regulating translesion synthesis (TLS), limiting unscheduled use of the error-prone TLS polymerases [23] . Recently, p21 has also been implicated in regulation of replication fork progression, although different results were reported as to whether p21 promotes DNA elongation [24] or suppresses fork speed [25] .
Interestingly, previous studies have demonstrated that p21 status is important for the responses to a combination of Checkpoint kinase 1 (Chk1) inhibition and irinotecan or gemcitabine [26, 27] . Cells deficient for p21 showed more DNA damage and cell death after Chk1 inhibition than p21 proficient cells, but the mechanism behind the increased damage was not known [26, 27] . Inhibition of Chk1, similar as for Wee1 inhibition, causes unscheduled replication initiation and DNA damage in S phase [28] [29] [30] . Taken together, this led us to investigate whether p21 status also affects the cellular responses to Wee1 inhibition, and whether S phase effects might be involved. Our study shows that loss of p21 leads to more S phase DNA damage and cancer cell death after Wee1 inhibition. These results could be of importance to guide the future clinical implementation of Wee1 inhibitors, as tumors with low p21 expression may be particularly sensitive.
Materials and methods

Cell culture, drug treatments and radiation
Human U2OS osteosarcoma cells, HCT116 colon cancer cells and Retinal Pigmented Epithelial (RPE) cells were cultured in DMEM (Dulbecco's modified Eagle's) (U2OS, HCT116) or DMEM/F12 (RPE) medium (both from Invitrogen), supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin/ Streptomycin (P/S) at 37°C in a humidified atmosphere with 5% CO 2 . The Wee1 inhibitor MK1775 (AZD1775) (Merck Calbiochem) was used at concentrations from 25nM to 1000nM. The Chk1 inhibitor AZD7762 (Selleck Chemicals) was used at 10nM to 400nM, and Nocodazole (Sigma) was used at 0.04 μg/ ml. Irradiation of cells was performed with an X-ray generator (Faxitron CP160, 160 kV, 6.3 mA) at a dose-rate of 1 Gy/min. Cells were irradiated immediately after addition of MK1775.
p21 siRNA transfection and isogenic cell lines U2OS cells were transfected with a pool of 4 siRNAs (SMARTpool) targeting p21 (CDKN1a), sequences: GAUGGAACUUCGACUUUGU, GCG AUGGAACUUCGACUUU, CGAUGGAACUUC GACUUUG and CGACUGUGAUGCGCUAACG (Sigma). Alternatively, an independent p21 siRNA was used when indicated (p21siRNA #2); Mission siRNA CDK1NA (p21), sequence: CUAAGAG UGCUGGGCAUUU (Sigma). Cells were subjected to treatment 48 hours post transfection. The HCT116 wild type (wt) and p21 negative (p21 -/-) cell lines were purchased from Horizon Discovery (HD R02-035), and p21 loss was verified by measuring p21 induction after radiation. RPE cells deficient for p21 were made by the CRISPR/cas9 method: To knock-out the CDKN1A gene, hTERT RPE-1 cells were transfected with a combination (1:1) of p21 CRISPR/Cas9 KO Plasmid (Santa Cruz, sc-400,013), and p21 HDR Plasmid and stable clones were selected by puromycin (10 μg/ ml). Integration of the HDR cassette to the CDKN1A locus was confirmed by sequencing, and loss of p21 expression by immunoblotting.
Flow cytometry
For analysis of protein expression in single cells, cells were fixed with 70% ethanol and stained with antibodies as described previously [31, 32] .The antibodies used were mouse anti-phospho-Histone H2AX (Ser139) (γH2AX) (05-636, Millipore), rabbit anti-phospho-RPA (Ser4/Ser8)(A300-245, Bethyl Laboratories), rabbit anti-phospho-Histone H3 (Ser10) (06-570, Millipore), rabbit anti-phospho-BRCA2 (Ser3291) (AB9986, Millipore), rabbit antiphospho-B-Myb (Thr487) (ab76009, Abcam), mouse anti-phospho-Ser/Thr-Pro MPM-2 (05-368, Millipore) and goat anti-R2 (sc-10,846, Santa Cruz). Secondary antibodies were Alexa Fluor 488 and 647 (Molecular Probes), Dylight 549 (VectorLabs) and Cy3 (Jackson ImmunoResearch) anti-mouse, antirabbit and anti-goat IgG. The directly conjugated antibody FITC conjugated anti-phospho-Histone H2AX (Ser139) (Millipore) was used where indicated. When indicated in the figure legend, barcoding was used as before [31] [32] [33] Celltiter-glo® and realtime-glo™ assays 500 U2OS cells (non-transfected or p21siRNA transfected), and 500 or 700 HCT116 cells (wt or p21 -/-cells, respectively), were seeded in 96 well plates (Sigma Aldrich, CLS3610-48EA) in medium containing inhibitors of indicated concentrations. When indicated, irradiation was performed directly after seeding. The RealTime-Glo kit (Promega) was used for viability assessment in U2OS cells 4-6 days later, and the results presented here are from the 4 days time point (similar results were obtained at the 5 and 6 days time points). The CellTiter-Glo kit (Promega) was used for assessing viability in HCT116 cells at 6 days. Relative viability was calculated in each experiment by mean luminescence signal of treated samples (duplicates were seeded for each condition) divided by mean luminescence signal of non-treated sample (or single-treated sample in the case of drug combination experiments).
Clonogenic survival assays
U2OS cells were either mock transfected or transfected with p21 siRNA. 48 hours after transfection, the cells were harvested and re-seeded at low density in 6cm culture dishes (BD Biosciences) with medium containing the Wee1 inhibitor MK1775 (100 or 300 nM). After 24 hours the cells were washed and new medium was added. Cells were then cultured for 14 days, fixed in 70% ethanol and stained with methylene blue. HCT116 cells (wt or p21 -/-) were seeded at low density in 6cm dishes, and after approximately 20 hours MK1775 (600 or 1000 nM) was added. 24 hours later the cells were washed and new medium was applied. Cells were then cultured for 11 (wt) or 13 (p21 -/-) days, fixed in 70% ethanol and stained with methylene blue. Colonies of 50 or more cells were counted as survivors. Survival fractions were calculated in each experiment as the average cloning efficiency (from 3 parallel dishes) after treatment with the inhibitors, divided by the average cloning efficiency for non treated cells. Thereafter the survival fraction of p21 deficient cells was calculated relative to the survival fraction of p21 proficient cells.
Immunoblotting
Cells were lysed in SDS boiling buffer (2% SDS, 10mM Tris-HCl pH 7.5, 100µM Na 3 VO 4 ), and immunoblotting was performed as described previously [32] . The following antibodies were used for blotting: rabbit anti-p21 (SC-756, Santa Cruz), mouse anti-CDK1 (9112, Cell Signaling), rabbit anti-Actin (A-5060, Sigma), rabbit anti-phospho-DNA-PKcs (S2056) (ab18192, Abcam), rabbit anti-phospho RPA (S4/S8) (A300-245) (Bethyl Laboratories), mouse anti-gamma-Tubulin (T6557, Sigma) and mouse anti-MCM7 (SC-65,469, Santa Cruz).
Statistical analysis
Statistical comparisons were made by Two-sample t tests. P < 0,05 was considered significant. Error bars represent standard error of mean (N = 3), unless otherwise stated in the figure legend.
Results
p21 deficiency causes increased DNA damage in S phase after wee1 inhibition
We previously showed that Wee1 inhibition by MK1775 causes DNA breakage in S phase cells [8, 32] . To address whether p21 could protect against such damage, we applied three isogenic cell systems for p21: HCT116 colorectal cancer (wt/p21 -/-), immortalized normal epithelial RPE (wt/p21 -/-) and U2OS osteosarcoma with and without p21 siRNA transfection. Lack of p21 expression was verified by Western blotting (Figure 1(a) ). The cells were treated with MK1775 for 24 hours, and the DNA damage marker γH2AX and cell cycle phase was assayed in individual cells by flow cytometry analysis. In all three systems, the p21 depleted cells showed significantly more DNA damage in S phase after MK1775 treatment compared to p21 proficient cells, as seen by a higher amount of S phase cells with strong γH2AX levels ( Figure 1(b) ). This was not due to a higher fraction of cells in S phase prior to MK1775 treatment, as the percentages of S phase cells were largely similar for the p21 deficient and proficient cells ( Figure S1A ). However, consistent with more replication damage, the U2OS cells deficient for p21 accumulated more in S phase upon MK1775 treatment (Figure 1 In these experiments we applied lower concentrations of MK1775 for U2OS cells (100-300nM) compared to the two other cell lines (600-1000nM), because U2OS cells are highly sensitive to MK1775-induced S phase DNA damage [32] . Next, we measured phosphorylation of DNA-PKcs S2056 and RPA S4/S8 by Western Blotting, common markers for DNA double strand breaks (DSBs) and replication stalling, respectively [34, 35] . Consistent with the results for γH2AX, the p21 negative cells showed stronger phosphorylation of both DNA-PKcs S2056 and RPA S4/S8 after MK1775 treatment compared to the p21 proficient cells (Figure 1(c) ). The enhanced phosphorylation of RPA S4/S8 in p21 deficient U2OS cells was verified by flow cytometry analysis ( Figure S2 ). Furthermore, simultaneous analysis of both phospho-RPA S4/S8 and γH2AX revealed that the S phase cells with strong phospho-RPA S4/S8 also displayed strong γH2AX levels, and vice versa ( Figure S2 ). Taken together, these results show that p21 protects cells from DNA damage in S phase after Wee1 inhibition.
The increased DNA damage in p21 deficient cells occurs specifically in S phase, but is not caused by elevated CDK activity
Because of the important role of p21 in controlling the transition from G1 to S phase, we asked whether the cells with high DNA damage might potentially have aberrantly entered from G1 into S phase during MK1775 treatment. To address this issue, we first treated p21 positive and negative U2OS and RPE cells with MK1775 in the presence of Nocodazole, a microtubule inhibitor which stops cells in mitosis and thereby prevents the cells from proceeding into a second G1 and S phase during the 24 hours treatment of Wee1 inhibition. Notably, the number of cells with strong γH2AX levels in S-phase was higher for the p21 negative cells also in the presence of Nocodazole (Figure 2(a) ). Hence, the increased DNA damage in p21 deficient cells arises in the first S phase during MK1775 treatment. Furthermore, we performed a different set of experiments where U2OS (± p21 siRNA) and HCT116 (wt/p21 -/-) cells were treated with a pulse of the thymidine analogue 5-Ethynyl-2´-deoxyuridine (EdU) immediately before adding the Wee1 inhibitor, and the γH2AX levels and cell cycle profiles of EdU positive cells were assayed at 6 or10 hours later, respectively. In this way we could follow the fate of cells that were in S phase at the time of adding MK1775, thus excluding all cells that were entering S phase from G1 phase during the treatment. Again, more p21 deficient cells showed strong γH2AX levels than p21 proficient cells (Figure 2(b) , top). In addition, the resulting cell cycle profiles of the EdU positive populations showed that p21 deficient S phase cells had more trouble progressing through the cell cycle after MK1775 treatment than p21 proficient S phase cells (Figure 2(b MK1775 treatment. Rather, the increased DNA damage occurs as a consequence of events occurring in S phase upon MK1775 treatment.
As unscheduled CDK activity is thought to mediate MK1775-induced DNA damage in S phase, and both p21 and Wee1 are well known CDK inhibitors [2, 5, 11] , we next addressed whether the increased DNA damage observed in p21 negative cells might be caused by increased CDK activity. We previously developed a flow cytometry based assay to measure CDK activity during specific cell cycle phases, by examining CDK-dependent phosphorylations [31, 32] . Using this method, we measured S phase CDK activity after 90 minutes of MK1775 treatment in p21 positive and negative U2OS, HCT116 and RPE cells. As expected and in concordance with previous studies [32] , Wee1 inhibition caused increased phosphorylation of all three markers in the assay (Figure 2(c,d) ). However, this CDK activity was not further increased in p21 negative cell lines (Figure 2(c,d) ), suggesting that loss of p21 does not cause increased CDK activity during S phase. Moreover, it has been shown that increased CDK activity upon Wee1 inhibition causes decreased levels of the Ribonucleotide Reductase subunit R2, which is essential for nucleotide production [36] . Consistent with the CDK activity results above, we observed a similar decrease in R2 levels after MK1775 treatment in p21 positive and negative cells ( Figure S3A and B) . Of note, transient depletion of p21 by siRNA in U2OS cells did cause a decrease in R2 levels (data not shown), but the MK1775-induced decrease was not bigger than in p21 proficient cells. Altogether, these results suggest that an S phase function of p21 can protect against MK1775-induced DNA damage, but this protection is not due to an effect of p21 in restraining S phase CDK activity.
Effects of p21 status on mitotic entry and G1-arrest after Wee1 inhibition
We next asked whether p21 status might also be important for mitotic entry or G1-arrest after MK1775 treatment. We performed flow cytometric analysis of the percentage of mitotic cells at 90 minutes and 24 hours after Wee1 inhibition in p21 positive and negative cells. As expected, the number of mitotic cells was increased after MK1775 treatment in all three cell systems (Figure 3(a,b) ), consistent with MK1775-induced mitotic entry. However, the effects of p21 loss on mitotic entry after MK1775 treatment varied between the cell lines and with different concentrations of the Wee1 inhibitor (no effects in U2OS cells; some effects in HCT116 and RPE cells) (Figure 3(a,b) ). Furthermore, the majority of the cells with strong S phase γH2AX were not positive for the mitotic marker phospho-H3 Ser10 and most of the mitotic cells were negative for γH2AX (Figure 3(c) ), indicating that the S phase DNA damage and mitotic entry are two separate effects after MK1775 treatment. Moreover, few cells showed induction of premature mitosis (H3P positive cells with <4N DNA content) after Wee1 inhibition, and p21 loss did not seem to increase this amount further (Figure 3(c) lower panels). The latter is in agreement with the CDK activity measurements above, where we observed no increase in S phase CDK activity in p21 negative cells compared to p21 positive cells after Wee1 inhibition (Figure 2(c,d) and S3). Next, we wanted to address whether Wee1 inhibition could induce a p21 dependent first or second-cycle G1-arrest. To examine first cycle G1-arrest, we compared the G1 population after 24 hours treatment with MK1775 and Nocodazole to the G1 population after treatment with Nocodazole alone. The results showed no indication of a strong first cycle G1-arrest in any of the cell lines (Figure 3(d) ). To measure second-cycle G1-arrest, we first treated the cells with MK1775 for 24 hours, followed by Nocodazole for the next 24 hours (Figure 3(e) ). Again, there was no indication of a strong G1-arrest after Wee1 inhibition in p21 positive or negative cancer cells, but the p21 positive RPE cells showed some G1 accumulation in the second cycle which was abrogated by loss of p21 (Figure 3 (e), bottom panels: 26.5% versus 8.8% G1 cells for RPE wt and p21 -/-cells, respectively). Taken together, these results show that the effects of Wee1 inhibition on mitotic entry and G1-arrest vary between cell lines, but overall, the differences in these responses between p21 proficient and deficient cells are less pronounced than the differences in S phase DNA damage (Figure 1) . We conclude that a major consequence of p21 deficiency is increased S phase DNA damage in response to the Wee1 inhibitor MK1775.
p21 protects cancer cells against Wee1 inhibition induced cell death
As mentioned above, p21 expression can be low in human tumors due to epigenetical suppression [12] [13] [14] [15] [16] . To address whether p21 might protect cancer cells from MK1775-induced cell death, we examined cell growth and viability and clonogenic survival of the p21 positive and negative U2OS and HCT116 cells. We first measured loss of cell viability by assessing the uptake of the non-permeable dye Pacific Blue at 3 days after treatment with MK1775 for 24 hours. Higher numbers of non-viable cells were observed after MK1775 treatment in p21 deficient compared to p21 proficient U2OS and HCT116 cells (Figure 4(a,  b) ). Similar effects were observed by measuring the percentage of cells with sub-G1 DNA content ( Figure  4(c,d) ). These effects were supported by CellTiterGlo/ RealTimeGlo growth assays, which showed reduced growth in the p21 deficient U2OS and HCT116 cells after MK1775 treatment compared to p21 proficient cells (Figure 4(e) ). Note that in the latter experiments the inhibitor was not washed off, but present for several days, and we therefore used lower concentrations of MK1775. Of note, the lowest concentrations (25-50 nM) slightly increased growth in p21 positive U2OS cells (Figure 4(e) ). Such growth stimulation has also been reported previously and is likely a cell type dependent effect associated with shorthening of the cell cycle after treatment with low and non-lethal concentrations of the Wee1 inhibitior [37] . Finally, we performed clonogenic survival assays in HCT116 and U2OS cells and observed reduced survival of p21 negative compared to p21 positive cells upon Wee1 inhibition (Figure 4(f,g) ). We conclude that for U2OS and HCT116 cancer cells, p21 deficiency leads to increased cell death in response to MK1775 treatment. Similar to Wee1 inhibition, inhibition of Chk1 also causes DNA damage in S phase [29] , and we recently showed that simultaneous inhibition of both Chk1 and Wee1 synergistically increases such damage [32] . As we found that p21 deficiency enhanced the S phase DNA damage and cell death after Wee1 inhibition (Figures 1, 2 and 4) , we reasoned that similar effects might be observed in response to Chk1 inhibition and upon simultaneous Chk1/Wee1 inhibition. To address this issue, we assayed cell growth by the CellTiterGlo/RealTimeGlo assays and γH2AX levels by flow cytometry. Cell growth after treatment with the Chk1 inhibitor AZD7762 was slightly more reduced in p21 deficient U2OS and HCT116 cells compared to p21 proficient cells ( Figure 5(a) ). Furthermore, the p21 deficient U2OS and HCT116 cells were more sensitive to the combined treatment of MK1775 and AZD7762 ( Figure 5  (b) ). The number of cells with strong γH2AX levels was also higher in p21 deficient HCT116 and U2OS cells after the combined treatment ( Figure 5(c) ), consistent with increased S phase DNA damage. These results show that p21 also protects against the S phase DNA damage in response to Chk1 inhibition or combined Chk1/Wee1 inhibition.
Finally, as Wee1 inhibitors are typically applied together with DNA damaging agents such as ionizing radiation, we also assessed the growth of p21 deficient and proficient U2OS and HCT116 cells upon treatment with 2 Gy of X-ray irradiation in combination with various concentrations of MK1775. Again, cell growth was most reduced in the p21 negative cancer cells ( Figure 5(d) ), indicating that p21 deficiency can also sensitize cancer cells to combination treatments of MK1775 with radiation.
Discussion
In this study we report that the p53 target and CDK inhibitor p21 can protect cells from S phase DNA damage induced by the Wee1 inhibitor MK1775. We also show that p21 deficiency can sensitize cancer cells to MK1775-induced cell death, as measured by cell viability, clonogenic survival and cell growth assays. Moreover, the p21 deficient cancer cells are also more sensitive to combination treatments of MK1775 and the Chk1 inhibitor AZD6772 or MK1775 together with ionizing radiation. Altogether these results provide a rationale for the application of Wee1 inhibitors in tumors with low levels of p21, and support recent studies indicating that p21 can have important functions in S phase.
p21 is known as a CDK inhibitor important in the G1 and G2 phases of the cell cycle. As p21 levels are low in S phase, the investigation into the -/-cells, measured by the RealTimeGlo (U2OS) or CellTiterGlo (HCT116) assays at 4 and 6 days, respectively, after treatment with MK1775 in the indicated concentrations and X-ray irradiation (2 Gy). Viability was calculated relative to the corresponding non-irradiated p21 proficient or defective sample (such as in Figure 4E ). Bottom graphs: Viability was calculated relative to the 2Gy but otherwise untreated samples, for p21 positive and negative cells respectively. Error bars: SEM (N = 3).
role of the remaining p21 in this cell cycle phase has been limited. Considering the acknowledged role of p21 in regulating CDK activity, we wondered whether this role could be important also during S phase when Wee1 is inhibited. Potentially, higher CDK activity after Wee1 inhibition in p21 negative S phase cells could be the cause of the higher DNA damage. However, we did not detect increased CDK activity after p21 loss by our flow cytometric measurements of CDK target phosphorylations (Figure 2(c,d) ). Furthermore, S phase levels of the CDK target R2 were also not altered in p21 deficient cells upon Wee1 inhibition ( Figure S3 ). It is therefore likely that other roles of p21 in S phase protects cells from DNA damage after Wee1 inhibition.
Interestingly, we have seen higher EdU uptake in p21 negative compared to p21 positive HCT116 cells, both before and after Wee1 inhibition ( Figure S4 ). This could possibly indicate that p21 is involved in restraining replication when Wee1 mediated restriction of replication is inhibited. Moreover, p21 has been implicated in promoting the Fanconi anemia (FA) DNA repair pathway [38] and regulation of translesion synthesis (TLS) [23] . The latter function could be of special importance, as the TLS factor DNA polymerase kappa has been shown to confer tolerance to Wee1 inhibition [39] . However, we have not been able to see any marked differences in FANCD2 and PCNA ubiquitination between p21 proficient and negative samples after Wee1 inhibition (data not shown). Conceptually, we therefore envision that p21 is involved in restraining replication after Wee1 inhibition, limiting S phase DNA damage and subsequent cell death, but the exact mechanism for how p21 is involved in this remains to be elucidated.
The Wee1 inhibitor MK1775 (now entitled AZD1775) is currently being investigated in more than fifty clinical trials for cancer treatment, as monotherapy or in combination with chemotherapeutic drugs and/or radiation (www.clinicaltrials. gov). There is therefore a need for more knowledge about what factors might be of importance with regards to sensitivity to Wee1 inhibition. Several preclinical studies suggest that p53 status may be important for the effects, and recently published results of phase I and II clinical studies show some enhanced sensitivity in p53 mutated cancers [3, [40] [41] [42] [43] [44] . There is emerging evidence that the expression of p21, a major p53 target [11] , can also be deregulated in cancers, as a result of epigenetic changes [12] [13] [14] [15] [16] . This, combined with our finding that p21 protects cancer cells against MK1775 induced death, suggest that p21 expression could be another factor to be taken into consideration when implementing Wee1 inhibition in the treatment of cancer.
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